 MONTREAL, July 15, 2021 GLOBE NEWSWIRE -- Theratechnologies, Inc. Theratechnologies, or Company TSX: TH NASDAQ: THTX, a biopharmaceutical company focused on the development and commercialization of innovative therapies, today reported financial results for the second quarter ended May 31, 2021 Q2 Fiscal 2021 and provided an update on its planned Phase 3 clinical trial evaluating tesamorelin for the treatment of nonalcoholic steatohepatitis NASH. 